NCT01002807View on ClinicalTrials.gov

Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

January 31, 2010

Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
DRUG

Dapagliflozin

Tablets, Oral, 10 mg, Single Dose

DRUG

Metformin XR

Tablets, Oral, 1000 mg, Single Dose

DRUG

Glucophage

Tablets, Oral, 1000 mg, Single Dose

Trial Locations (1)

78744

Ppd Development, Lp, Austin

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

AstraZeneca

INDUSTRY